Drugs / Realgar-Indigo Naturalis Formulation
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06982274 | Oct 2023 → Nov 2028 expected | acute promyelocytic leukemia | Cancer Institute of the State of São Paulo | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07075250 | Sep 2025 → Dec 2028 expected | carcinoma | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Realgar-Indigo Naturalis Formulation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07075250 ↗ |
| Route | Oral | “Oral Arsenic (Realgar-Indigo Naturalis Formulation)” NCT06982274 ↗ |